Status:
UNKNOWN
E-cadherin and Integrin Alpha v Beta 1 in Vitiligo
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Vitiligo
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The purpose of this clinical trial is to study the effect of Narrow Band UVB on E-cadherin and integrin alpha v beta 1 as representatives of adhesion molecules in non-segmental vitiligo in a trial to ...
Eligibility Criteria
Inclusion
- All clinically diagnosed cases of non-segmental vitiligo .
- Patients with VIDA +1 or more (new/expanding lesions active in time period of 6-12 months ago) will be included in the trial. Activity of vitiligo will be evaluated through Vitiligo Disease Activity (VIDA) Score.
Exclusion
- Patients who have stable disease at the time of study i.e. no progression of existing disease or appearance of new lesions in the last six months.
- Patients receiving treatment for vitiligo 3 months prior to the study.
- Patients with contraindications for phototherapy.
- Patients with current/history of any systemic and/or dermatological diseases affecting the immune system as autoimmune diseases and malignancy.
Key Trial Info
Start Date :
June 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05287776
Start Date
June 1 2019
End Date
December 1 2022
Last Update
March 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasr El Ainy university hospital, Faulty of medicine,Cairo university
Cairo, El Manial, Egypt, 11956